Figure 2
Total average cost per patient of managing grade 3–4 adverse events associated with bevacizumab plus IFN or with sunitinib in patients with metastatic RCC. IFN=interferon-α2a; RCC=renal call carcinoma. aMotzer et al, 2007; bNegrier et al, 2008; cEscudier et al, 2007.
